Olga Krasnovskaya
Overview
Explore the profile of Olga Krasnovskaya including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
85
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Spector D, Krasnovskaya O, Bykusov V, Isaeva Y, Akasov R, Zharova A, et al.
ChemMedChem
. 2025 Jan;
:e202400786.
PMID: 39791228
Light induced release of cisplatin from Pt(IV) prodrugs is a promising tool for precise spatiotemporal control over the antiproliferative activity of Pt-based chemotherapeutic drugs. A combination of light-controlled chemotherapy (PACT)...
2.
Krasnovskaya O, Abramchuk D, Vaneev A, Gorelkin P, Abakumov M, Timoshenko R, et al.
ACS Omega
. 2024 Nov;
9(43):43376-43384.
PMID: 39493999
Five bifunctional copper chelating agents, , designed to prevent beta-amyloid (Aβ) aggregation, were synthesized, and the leader compound () was chosen. acts as a bifunctional chelator that can interact with...
3.
Lifanovsky N, Spector D, Egorov A, Mazur D, Bubley A, Belousov A, et al.
Spectrochim Acta A Mol Biomol Spectrosc
. 2024 Oct;
326:125227.
PMID: 39383547
This paper reports synthesis and characterization of three new coumarin-fused NIR BODIPY dyes 16-18, as well as the detailed study of their optical response to exposure with X-rays (up to...
4.
Abramchuk D, Voskresenskaya A, Kuzmichev I, Erofeev A, Gorelkin P, Abakumov M, et al.
Eur J Med Chem
. 2024 Jul;
276:116682.
PMID: 39053190
Timely diagnosis and therapy of Alzheimer's disease remains one of the greatest questions in medicinal chemistry of neurodegenerative disease. The lack of low-cost sensors capable of reliable detection of structural...
5.
Spector D, Bubley A, Zharova A, Bykusov V, Skvortsov D, Ipatova D, et al.
ACS Appl Bio Mater
. 2024 May;
7(5):3431-3440.
PMID: 38697834
Light-induced release of cisplatin from Pt(IV) prodrugs represents a promising approach for precise control over the antiproliferative activity of Pt-based chemotherapeutic drugs. This method has the potential to overcome crucial...
6.
Bubley A, Erofeev A, Gorelkin P, Beloglazkina E, Majouga A, Krasnovskaya O
Int J Mol Sci
. 2023 Jan;
24(2).
PMID: 36675233
Alzheimer's disease (AD) is a neurodegenerative disorder which is characterized by β-amyloid (Aβ) aggregation, τ-hyperphosphorylation, and loss of cholinergic neurons. The other important hallmarks of AD are oxidative stress, metal...
7.
Spector D, Erofeev A, Gorelkin P, Skvortsov D, Trigub A, Markova A, et al.
Dalton Trans
. 2023 Jan;
52(4):866-871.
PMID: 36629146
A design of Pt(IV) prodrugs with tumor cell targeting moieties leading to increased selectivity is of interest. Herein, we designed a novel Pt(IV) prodrugs with COX-inhibitor naproxen, long-chain hydrophobic stearic...
8.
Krasnovskaya O, Kononova A, Erofeev A, Gorelkin P, Majouga A, Beloglazkina E
Int J Mol Sci
. 2023 Jan;
24(1).
PMID: 36613679
Currently, more than 55 million people live with dementia worldwide, and there are nearly 10 million new cases every year. Alzheimer's disease (AD) is the most common neurodegenerative disease resulting...
9.
Spector D, Pavlov K, Beloglazkina E, Krasnovskaya O
Int J Mol Sci
. 2022 Dec;
23(23).
PMID: 36498837
Pt(IV) prodrugs remain one of the most promising alternatives to conventional Pt(II) therapy due to their versatility in axial ligand choice and delayed mode of action. Selective activation from an...
10.
Krasnovskaya O, Spector D, Erofeev A, Gorelkin P, Akasov R, Skvortsov D, et al.
Dalton Trans
. 2021 May;
50(23):7922-7927.
PMID: 34037020
In a recent research paper Dr. Suxing Jin et al. reported two multispecific PtIV complexes DNP and NP with non-steroidal anti-inflammatory drug naproxen (NPX) as the axial ligand(s). Herein, we...